What is Claritev's gross profit margin?

What guidance did Claritev's management provide for the next earnings period?

What is the revenue and EPS growth rate for Claritev year over year?

What is Claritev's latest dividend and current dividend yield?

Did Claritev beat or miss consensus estimates last quarter?

What were the key takeaways from Claritev’s earnings call?

What factors drove the changes in Claritev's revenue and profit?

What is the market's earnings forecast for Claritev next quarter?

- **Q3 Growth Milestones**: 6.7% revenue and 9.5% EBITDA growth, best in 12 quarters.
- **Client Stability**: Top 10 clients renewed, including a previously challenging account.
- **Pipeline Momentum**: $60 million ACV booked, 67% pipeline growth year-to-date.
- **International Expansion**: UAE deals signed ahead of schedule, exploring MENA healthcare solutions.
- **2026 Outlook**: 2.8-3.2% revenue growth, 62.5-63% EBITDA margin guidance.
- **NSA Performance**: 80% provider win rate, but Claritev's automation reduces costs by 70%.
- **Cash Flow Strength**: $113 million free cash flow, 73% cash conversion ratio.

**【CEO Summary Section】**
- Claritev achieved a 6.7% year-over-year revenue growth and 9.5% adjusted EBITDA growth in Q3, marking the 'Year of the Turn'.
- Renewed contracts with top 10 clients, including a previously challenging client, providing stability and visibility.
- Expanded into 6 market verticals, adding 5 new logos and closing 180 opportunities, with a 67% increase in pipeline year-to-date.
- Launched international expansion in the UAE, signing deals ahead of schedule, and exploring innovative solutions for healthcare challenges.
- Rebranding efforts resulted in 100%+ website traffic growth and increased market engagement.

**【CFO Financial Commentary】**
- Q3 revenue: $246 million (6.7% YoY growth), adjusted EBITDA: $155.1 million (9.5% YoY growth), with EBITDA margins at 63.1%.
- Core service lines grew: network revenue (+15%), analytics (+4.2%), payment integrity (+7%).
- ACV signings reached $60 million for the year, with 60-65% expected to convert to 2026 revenue.
- Free cash flow of $113 million (strongest in 9 quarters), with net leverage below 8x.
- Guidance updated: 2.8-3.2% revenue growth and 62.5-63% EBITDA margin for 2025.

**【Q&A Highlights】**
- **2026 Outlook**: Mid-single-digit revenue growth expected, driven by healthcare inflation (6-9%) and pipeline conversion.
- **ACV Conversion**: $60 million ACV booked in 2025, with 60-65% converting to 2026 revenue.
- **NSA Business**: 80% provider win rate in disputes, but Claritev's automation reduces costs by 70%.
- **Client Renewals**: Top 10 clients renewed at stable terms, with focus on upselling new products.
- **Risks**: Regulatory uncertainty and healthcare inflation variability could impact 2026 performance.

Claritev Corporation (CTEV) Q3 2025 Earnings Call Transcript

Network Services

Analytics-Based Services

Payment and Integrity Services

CTEV

CTEV fundamentals

You can ask Aime